諾和諾德與 Anthropic 合作，利用 Claude 加速藥物開發

9月16日（路透）— 諾和諾德（Novo Nordisk）已與 Anthropic 合作，將使用這家 AI 巨擘的 Claude 模型，加速新藥的發現與開發，兩家公司週三表示。Sept 16 (Reuters) - Novo Nordisk has partnered with Anthropic to use the AI giant's Claude models to speed up discovery and development of new medicines, the companies said on Wednesday.

以下是更多細節：Here are more details:

• 兩家公司表示，這家丹麥製藥商將先在其研發工作流程中測試 Anthropic 模型與 Claude Science，並處理雙方共同能力可發揮最大影響的科學問題。• The Danish drugmaker will initially test Anthropic models and Claude Science in its research and development workflows, and address scientific problems where their joint capabilities can have the greatest impact, they said.

• 「但除此之外，AI 工具也能提供全新的科學機會，並協助推理與理解人類生物學及藥物機制，」諾和諾德執行長麥克・杜斯達（Mike Doustdar）表示。• "But beyond this, AI tools can also offer completely new scientific opportunities and aid reasoning and understanding of human biology and drug mechanics," Novo CEO Mike Doustdar said.

• 製藥商正日益轉向人工智慧，以加速研發，並提升整體產品管線的效率。• Drugmakers are increasingly turning to artificial intelligence to accelerate R&D and improve efficiency across their pipelines.

• 這家 Wegovy 製造商也將使用 Anthropic 的前沿模型，強化 AI 驅動的軟體開發。• The Wegovy maker will also use Anthropic's frontier models to strengthen AI-driven software development.

• 「透過讓頂尖研究人員使用安全、有能力且值得信賴的前沿模型，我們可以縮短研究時程、改善成果，並發現能顯著改善人類生活的藥物與療法，」Anthropic 執行長達里奧・阿莫迪（Dario Amodei）表示。• "By giving leading researchers access to safe, capable, and trusted frontier models, we can shorten research timelines, improve outcomes, and discover medicines and treatments that significantly improve human life," said Dario Amodei, CEO of Anthropic.

• 與此同時，AI 產業領袖對於企業應以多快速度開發這項日益強大的技術意見分歧。• Meanwhile, AI industry leaders are split over how fast companies should develop the increasingly powerful technology.

• 諾和諾德已使用 Claude 自動產生試驗報告，並將病患文件製作時程從數月縮短至數分鐘。• Novo already uses Claude to automate trial report generation, and trim timelines for patient documentation creation from months to minutes.

（班加羅爾 Sriparna Roy 報導；Leroy Leo 編輯）(Reporting by Sriparna Roy in Bengaluru; Editing by Leroy Leo)